🔴 CALC is trading 5.7% down today as trial discontinuation fallout continues

CALC is trading 5.7% down at $0.90 in pre-market, extending recent weakness following a major clinical trial setback.

• The company recently announced it would discontinue its key Auxora trial for acute kidney injury, a decision that initially triggered a 76% share price collapse.
• Ongoing selling pressure reflects investor concerns as the market reassesses CalciMedica’s remaining pipeline prospects and risk profile.
• The stock continues to face downward momentum while investors digest the long-term impact of the trial's termination.